Stockwinners Market Radar for August 27, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment buys 30K shares of Blade Air Mobility today

19:50 EDT Exicure Inc trading halted, news pending

19:05 EDT Sweetgreen CEO Neman sells 169,772 class A shares - In a regulatory filing, Sweetgreen CEO Jonathan Neman disclosed the sale of 169,772 class A common shares of the company on August 26 at a price of $35.77 per share.

18:12 EDT NextNav director buys $1.7M in common stock as part of option exercise - In a regulatory filing, NextNav disclosed that its director Neil Subin bought 250K shares of common stock on August 23rd as part of option exercise in a total transaction size of $1.73M. Shares of NextNav are up 5.2% afterhours at $7.33.

17:56 EDT Weyerhaeuser director Monaco buys 31,500 common shares - In a regulatory filing, Weyerhaeuser director Albert Monaco disclosed the purchase of 31,500 common shares of the company on August 26 at a price of $31.377 per share.

17:45 EDT Lyft launches rider verification pilot program - "Safety and security are important for everyone in our community (LYFT), no matter what seat they're in. Drivers have always been required to verify their profile. Now we're encouraging riders to take this safety measure, too. This will help drivers confirm that the person they're riding with is who they say they are...Our process includes cross-checking a rider's personal information, like their legal name and phone number, using trusted, third-party databases. If their information can't be validated, riders may be asked to upload an ID. Any information provided is protected in accordance with our privacy policy.,' said the company in part..."When you're in a car, it's close quarters. This gives me more confidence in accepting rides."Brian R., driver since 2017..Other companies in the space include Uber (UBER) and Waymo (GOOG;GOOGL) . Reference Link Reference Link

17:35 EDT Statement from President Biden on anti-obesity medications pricing - "Americans pay two to three times more than people in other countries for the exact same prescription drugs. It's completely unacceptable. Vice President Harris and I have taken action to lower the cost of the medications Americans rely on by allowing Medicare to negotiate drug prices for the first time in history - negotiations which will continue on additional drugs next year. We've also capped the cost of insulin at $35 a month for those with Medicare, and required drug companies to pay rebates back to Medicare if they raise their prices faster than inflation. But too many people still struggle to afford their medications.That is why last month Senator Sanders and I called on drug manufacturers to lower their prices on popular drugs to combat obesity, diabetes, and cardiovascular disease. The prices of these drugs can be up to six times higher in America than in Canada, Denmark, and other similar countries. Today, I am pleased to see one of these manufacturers, Eli Lilly, taking steps to lower their price by offering a direct-to-consumer version of their medication for less than half the price they used to charge. This is a welcome first step for American families struggling to access these drugs. But it is critical that drug companies lower their prices across the board. The Vice President and I will keep fighting to make sure all Americans can access the medications they need." Companies in the space include: Eli Lilly (LLY), Structure Therapeutics (GPCR), Novo Nordisk, AstraZeneca (AZN), Pfize,r (PFE),Novo Nordisk (NVO)... Reference Link

17:29 EDT AeroVironment awarded $990M U.S. Army contract - AeroVironment was awarded a $990,000,000 hybrid (cost-plus-fixed-fee and firm-fixed-price) contract to provide an organic, stand-off capability to dismounted infantry formations capable of destroying tanks, light armored vehicles, hardened targets, defilade and personnel targets. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of Aug. 26, 2029.

17:16 EDT Nature's Sunshine Products announces equipment malfunction at Utah facility - Nature's Sunshine Products announced that an equipment malfunction occurred at their Spanish Fork, Utah manufacturing facility early yesterday morning. The facility was evacuated and local emergency services were called to the scene to help manage the incident. All personnel are safe and accounted for, and two individuals were seen by EMTs and released to leave the facility. The company is working to determine the cause of the malfunction, which resulted in a small fire, and to assess the extent of the damage to the facility. A portion of the facility will temporarily be closed for repairs while normal operations continue in unaffected areas.

16:54 EDT Meta Spark's platform of 3rd party tools and content to shut amid AI moves - "Following a thorough assessment, we have made the decision to shut down Meta Spark's platform of third party tools and content, effective Tuesday, January 14. This means that the Augmented Reality or AR, effects built by third parties , including brands and our wider community of AR Creators , will no longer be available beginning on this date. AR Effects owned by Meta will continue to be available to our users across our Family of Apps....This decision is part of our larger efforts to prioritize the products we believe will best serve the future needs of our consumers and business customers alike. We are committed to making this transition as smooth as possible. Those who use Spark and our third-party AR Effects can continue to use these tools across our Family of Apps until January 14 . To stay up to date on important details, next steps and recommended actions before Meta Spark goes away, visit our FAQs," said the company in a release. Reference Link

16:44 EDT Maxeon Solar CFO Kai Strohbecke to step down, Ken Olson named interim CFO - In a regulatory filing, Maxeon Solar announced that Ken Olson, currently Senior Vice President, Global Treasurer of the company, has been appointed interim CFO, effective September 1. Kai Strohbecke will step down as the CFO of the company on August 31, in accordance with the company's Form 6-K filed on June 6. The company has commenced a formal search for its new CFO.

16:37 EDT Nordstrom jumps 8% to $22.89 after Q2 earnings beat, raised guidance midpoint

16:32 EDT Quantum-Si names Todd Bennet chief commercial officer - Quantum-Si Incorporated announced that Todd Bennett will join QSI as the Company's new Chief Commercial Officer effective September 16, 2024, John Vieceli, Ph.D. has been named Chief Product Officer and Lindsay Thompson has been named Chief Human Resources Officer. "I am pleased to welcome Todd to QSI as we look to leverage his breadth of industry experience to accelerate the global adoption of Platinum. Todd is a highly regarded commercial leader in our industry and his track record of building high performing commercial teams and driving market adoption of new technologies is perfectly aligned with our needs for the next phase in the commercialization of our Next-Generation Protein Sequencing technology," said Jeff Hawkins, Chief Executive Officer of Quantum-Si.

16:31 EDT Granite awarded roughly $45M contract to reconstruct John Wilkie rest area - Granite has been awarded an approximately $45M contract to reconstruct and modernize the John Wilkie Safety Roadside Rest Area along the Interstate 40 corridor by the California Department of Transportation. Project funding will come from Caltrans and was included in Granite's second-quarter CAP. This project marks the fifth in a series of initiatives to improve safety and infrastructure along I-40. The project scope includes constructing a modern rest area for motorists. Given the significant distance from the nearest town, this upgraded rest area will provide a safe place for travelers to rest and recover, enhancing safety along this stretch of the interstate. Previous projects included filling in the median, flattening slopes adjacent to the roadway, and creating recovery areas for vehicles that leave the highway.

16:19 EDT Shake Shack to close nine company-owned and operated Shacks - In a regulatory filing, Shake Shack stated that the company "regularly evaluates its portfolio of Company-owned and operated Shack restaurants. As a result, it has identified locations that are underperforming at the Shack level in part due to changes in the trade area and, in some cases, are negatively impacting other Shacks within their proximity by cannibalizing sales. These Shacks are not projected to provide acceptable returns in the foreseeable future. As a result of this evaluation, the Company has determined to close nine Company-owned and operated Shacks in California, Ohio and Texas. These closings are expected to optimize the Company's footprint in these states and maximize profitable growth moving forward, and are not anticipated to impact the Company's plans to open additional Shacks in these states. The Company currently does not anticipate closing any additional Shacks based on this evaluation for the foreseeable future. Management in these Shacks will be offered a position in neighboring Shacks and hourly team members will be eligible for rehire at other Shacks, and hourly team members and any managers who do not accept a transfer will receive up to 60 days pay. This Shack closure plan was communicated to impacted employees on August 27, 2024 and is expected to be completed by September 25, 2024, subject to finalizing third-party agreements and other contingencies. The Company expects to record cumulative pretax charges in a range of approximately $28.0 to $30.0 million during the third quarter ending September 25, 2024 as a result of these Shack closures. Cash costs are expected to be in a range of approximately $14.0 to $15.2 million. Included in these cash costs are pretax charges currently expected to be in a range of $12.8 to $13.6 million related to lease termination costs and future lease obligations; employee-related costs currently expected to be in a range of approximately $1.0 to $1.2 million; and other cash costs currently expected to be in a range of approximately $0.2 to $0.4 million, which will primarily consist of charges related to Shack-related closing expenses. Non-cash costs are expected to be in a range of approximately $14.0 to $14.8 million and primarily consist of asset impairment, accelerated depreciation, and asset write-offs." Reference Link

16:13 EDT AvePoint announces commencement of offer to acquire outstanding public warrants - AvePoint "announced that it has commenced an offer to purchase all of its outstanding public warrants to purchase shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 in cash, without interest. AvePoint is also soliciting consents to amend the Warrant Agreement, dated September 16, 2019, by and between Apex Technology Acquisition Corporation and Continental Stock Transfer & Trust Company, which governs all of the Warrants, to permit AvePoint to redeem each outstanding Warrant for $2.00 in cash, without interest, which is 20% less than the price applicable to the Offer. Pursuant to the terms of the Warrant Agreement, the adoption of the Warrant Amendment will require the consent of holders of at least 50.1% of the then outstanding Warrants. If the holders of more than 50.1% of the outstanding Warrants agree to consent to the Warrant Amendment in the Consent Solicitation, if the other conditions of the Offer do not occur or, if they occur, are waived, then the Warrant Amendment will be adopted."

16:11 EDT Cipher Mining to acquire West Texas data center for $67.5M - Cipher Mining "announced it has entered into a term sheet to acquire a new site in West Texas for a cash payment of $67.5 million and a variable fee of $3/MWh for the initial five years after the energization of the site. The site features 300 MW of front-of-the-meter capacity, a newly constructed, fully energized, high-to-mid voltage substation, and all necessary regulatory approvals and contracts. As part of the transaction, Cipher will also acquire the 250 acres of land surrounding the substation and agreements necessary to participate in the ERCOT market. The Company is completing due diligence on the site and expects to close the transaction in September."

16:10 EDT Nordstrom sees FY24 SSS flat to 2.0% growth - Prior view was comparable sales range of 1.0% decline to 2.0% growth.

16:10 EDT Direct Digital receives additional delinquency notice from Nasdaq - Direct Digital Holdings reported that the Company received an additional delinquency notice from the Listing Qualifications Department of The Nasdaq Stock Market on August 21, which indicated that, as a result of the delay in the Company's filing of its Quarterly Report on Form 10-Q for the period ended June 30 by the applicable due date, the Company was not in compliance with Nasdaq Listing Rule 5250, which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC. The additional delinquency could serve as an additional basis for the delisting of the Company's securities from Nasdaq. Neither the Notice nor the Company's non-compliance with the Rule will have an immediate effect on the listing or trading of the Company's securities on Nasdaq, which will continue to trade on The Nasdaq Capital Market under the symbol "DRCT." The Company continues to work diligently to complete and file the Delayed Reports with the SEC and thereby evidence compliance with the Rule as soon as practicable.

16:08 EDT TechPrecision discloses Nasdaq listing deficiency notice - TechPrecision announced it received a notice on August 21, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 with the Securities and Exchange Commission.

16:07 EDT Tenon Medical names Kevin Williamson as new CFO - Tenon Medical announced it has appointed Kevin Williamson as Chief Financial Officer. Mr. Williamson's appointment succeeds the previously disclosed retirement of Steve Van Dick from the role of Chief Financial Officer. Mr. Williamson most recently served as the Chief Financial Officer at Accelus Inc., a medical device company focused on expandable spinal implant technology. In this role, Mr. Williamson was responsible for the finance organization, in addition to the investor relations and IT functions.

16:07 EDT Monopar Therapeutics regains compliance with Nasdaq minimum bid price rule - Monopar Therapeutics announced that it received notice from The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company's common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.

16:02 EDT Life Time Group plans to build new athletic country club in Austin - Life Time announced plans to bring a new athletic country club to South Lamar neighborhood of Austin, Texas as part of the dynamic four-acre mixed-use development - The Bouldin. A mid- to late-2025 opening is anticipated for this luxurious Life Time location. The 57,700-square-foot Life Time club will occupy the first two floors of the four-story building. Highlights include recovery and rejuvenation spaces, a full bar and social lounge, best-in-class small and large group training programs, a coworking space and a co-ed bath house with hot tubs, cold plunges, sauna and steam rooms. The Bouldin project will include more than 300 Class A multi-family units, two restaurants (Postino and Paperboy), a four-story retail and office building and two levels of underground parking, providing convenience for Life Time members and residents alike. Construction of Life Time Austin South Lamar is set to begin later this year.

16:00 EDT Leonardo DRS awarded $117M production order for family of weapon sights - Leonardo DRS announced that it has received an order for continued production of its next-generation thermal weapon sights for the U.S. Army. The production order for $117M was made under the current Family of Weapon Sights - Individual IDIQ contract. Leveraging DRS's uncooled thermal imaging technology, FWS-I is a stand-alone, clip-on weapon sight that connects wirelessly to helmet-mounted vision systems including the enhanced night vision goggle binoculars and the next-gen integrated visual augmentation system and provides rapid target acquisition capabilities to the soldier. It gives users the ability to acquire targets day or night and in a range of degraded environmental conditions, providing strategic and tactical advantages on the battlefield. "This cutting-edge technology ensures soldiers will have the most advanced weapon sight systems on the battlefield today," said Jerry Hathaway, senior vice president and general manager of DRS's Electro-Optical Infrared Systems business. "We are proud the U.S. Army recognizes us as a trusted partner to continue to deliver this vital technology to our warfighters."

15:21 EDT Meta Platforms and Sage in pact to expand the use of geothermal power - Earlier at the U.S. Department Energy's or DOE, Catalyzing Next Generation Geothermal Development Workshop, Sage Geosystems Sage and Meta Platforms announced a new agreement that would significantly expand the use of geothermal power in the U.S. and would be the first use of next generation geothermal power east of the Rocky Mountains...This partnership will deliver up to 150 MW of new geothermal baseload power to support Meta's data center growth...." "The U.S. has seen unprecedented growth in demand for energy as our economy grows, the manufacturing sector booms thanks to the Biden-Harris Administration's Investing in America agenda, and new industries like AI expand," said U.S. Energy Deputy Secretary David Turk. "The Administration views this increased demand as a huge opportunity to add more clean, firm power to the grid and geothermal energy is a game-changer as we work to grow our clean power supply." The partnership between Sage and Meta signifies a major step forward in the quest for sustainable energy solutions, reinforcing Sage's position as a leader in the geothermal revolution and Meta's dedication to pioneering clean energy initiatives. In addition to this first of a kind geothermal project, Meta continues to invest in carbon-free energy to support its data centers and support the transition to a cleaner and more reliable grid. The first phase of this innovative project will aim to be online and operating in 2027.

14:37 EDT Pono Capital Two Inc trading halted, volatility trading pause

13:20 EDT Worldwide smartphone market forecast to grow nearly 6% in 2024, IDC says - Worldwide smartphone shipments are forecast to grow 5.8% year over year in 2024 to 1.23B units, according to the International Data Corporation Worldwide Quarterly Mobile Phone Tracker. "The 12% growth in the first quarter, followed by 9% growth last quarter, has brought improved optimism about how 2024 will play out in the second half of the year. Affordable Android smartphones continue to grow rapidly in emerging markets coming off a difficult two years while premium markets are starting to embrace GenAI smartphones, generating excitement and renewed interest in the industry," said IDC's report. Reference Link

12:36 EDT Greif increases quarterly dividend to 54c per share - Greif announced that its Board of Directors has declared quarterly cash dividends of 54c per share on its Class A Common Stock, and 81c per share on its Class B Common Stock. Dividends are payable on October 1, 2024, to stockholders of record at the close of business on September 16, 2024.

12:00 EDT Lumen falls -10.4% - Lumen is down -10.4%, or -64c to $5.49.

12:00 EDT Gaotu Techedu falls -14.8% - Gaotu Techedu is down -14.8%, or -60c to $3.48.

12:00 EDT Bill rises 7.1% - Bill is up 7.1%, or $3.53 to $53.30.

11:29 EDT Senator Rubio calls on Deere to 'prioritize American workers' - Senator Marco Rubio said in a press release, "Recently, after receiving public backlash, John Deere ended several ridiculous Diversity, Equity, and Inclusion policies. Meanwhile, the company has laid off 2,000 American workers as it shifts production from the United States to Mexico. U.S. Senator Marco Rubio sent a letter to John Deere Chairman and CEO John May highlighting the need for patriotic companies to prioritize American workers and their families...America needs a strong manufacturing sector to build the tractors, combines, and other implements that make our country's agricultural self-sufficiency and leadership possible. American corporations, like John Deere, have a duty to their workers, nation, customers, and shareholders." Reference Link

11:02 EDT Ginkgo Bioworks awarded CDC contract - The CDC awarded a traveler-based genomic surveillance program contract to Ginkgo Bioworks according to a post to the SAM.gov website. The original published date of the post is August 26. Reference Link

10:34 EDT DXC Technology, Pluxee partner to optimize transaction processing in Brazil - DXC Technolog will collaborate with Pluxee inheriting the legacy of Sodexo Benefits and Rewards, to process benefit card transactions for the company's 7.1 million users in Brazil. The Pluxee Card helps create opportunities for business by linking recognition, incentive, and employee benefits strategies into one digital payment mechanism. The company handles up to 400 transactions per second between cardholders and commercial entities, enabled by transaction speed and service reliability. DXC will provide secure and agile processing of contactless card activities, one of Pluxee's digital benefits, which offers cashback on purchases made with the cards to enhance user satisfaction, loyalty, and retention.

10:32 EDT Legend Biotech announces cilta-cel approval in China for multiple myeloma - Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (GNNSF), announced they have received approval from the China National Medical Products Administration for its cell therapy product, ciltacabtagene autoleucel. This groundbreaking treatment is approved for use in adult patients with relapsed or refractory multiple myeloma who have previously undergone at least three prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent. The approval of cilta-cel provides a novel treatment for patients in China who have not benefit from traditional therapies. Cilta-cel is a gene-modified autologous chimeric antigen receptor T cell therapy targeting B-cell maturation antigen. It is administered via intravenous infusion. Cilta-cel features a unique CAR structure composed of two BCMA-targeting, heavy-chain, single-domain antibodies. This design allows cilta-cel to bind the BCMA-expressing myeloma cells, and induce activation and proliferation of T cells to eliminate tumor.

10:30 EDT SEI Investments chairman Alfred sells $4.83M of shares - SEI Investments Executive Chairman Alfred West disclosed the sale of 71,582 shares at an average price of $67.52, for a total amount of $4.83M. West still owns 7.61M shares of SEI Investments.

10:15 EDT Voxx jumps after Gentex buys shares at $5, offers buyout - On May 31, Gentex (GNTX) submitted a preliminary, non-binding proposal to Voxx (VOXX) that outlined certain terms on which Gentex would consider acquiring all of the outstanding shares of the company not currently owned by Gentex, according to a regulatory filing. The proposal was subject to a number of conditions, including, the negotiation and execution of definitive agreements and the approval of the transaction by shareholders of Voxx and it provided that Gentex CEO Steve Downing would recuse himself from any discussions about the proposal or alternative transactions. The proposal was reviewed by the board without the participation of Downing and Voxx subsequently advised Gentex that the board, without the participation of Downing, determined not to proceed with Gentex on the basis of the proposal at that time, but indicated that it would invite Gentex to participate in any strategic process that the board might initiate. Following Gentex's purchase of shares in August, Gentex and Voxx entered into a customary confidentiality agreement that included, among other things, a standstill provision. Gentex this morning a 31.97% stake, equating to over 6.46M shares. On August 23, Gentex entered into stock purchase agreement with Avalon Park to acquire 3,152,500 shares of class A common stock of Voxx at a price of $5.00 per share. Voxx, which also announced this morning that its board has been conducting an exploration of strategic alternatives in connection with its ongoing effort to maximize shareholder value, is up 84% to $5.24 in early trading.

10:03 EDT Gentex raises stake in Voxx, submitted proposal to acquire all shares

10:02 EDT Paltalk Inc trading halted, volatility trading pause

10:00 EDT Toyota rises 3.1% - Toyota is up 3.1%, or $5.62 to $186.19.

10:00 EDT Energizer rises 5.8% - Energizer is up 5.8%, or $1.75 to $32.09.

10:00 EDT Gaotu Techedu falls -9.8% - Gaotu Techedu is down -9.8%, or -40c to $3.68.

09:57 EDT GH Research PLC trading halted, volatility trading pause

09:48 EDT Energizer rises 3.6% - Energizer is up 3.6%, or $1.08 to $31.42.

09:48 EDT LandBridge rises 3.8% - LandBridge is up 3.8%, or $1.45 to $39.97.

09:48 EDT Lumen falls -9.0% - Lumen is down -9.0%, or -55c to $5.57.

09:36 EDT Knightscope announces two new contracts for ECDs - Knightscope announces two new contracts for its Emergency Communication Devices. An existing client - a college in southern California - is expanding their system by replacing a legacy competitive product with Knightscope's K1 Retrofit Kits, the Knightscope Emergency Management System and a Full Service Maintenance Plan. Additionally, a university in North Dakota issued a purchase order for three K1 Blue Light Towers, one K1 Blue Light E-Phone and KEMS.

09:27 EDT Lexaria Bioscience announces first results from second GLP-1 human pilot study - Lexaria Bioscience announces that the first results from human pilot study #2, GLP-1-H24-2, have been received. Lexaria's DehydraTECH-processed Rybelsus evidenced a trend toward higher overall absorption compared to Rybelsus that was not processed with DehydraTECH. Since Lexaria has already demonstrated superior pharmacokinetic performance of its DehydraTECH-processed Rybelsus under the recommended dosing conditions on an empty stomach in previously announced human pilot study #1, GLP-1-H24-1, it was deemed to be of scientific interest to learn whether the DehydraTECH advantages were also experienced under fed conditions. The DehydraTECH-processed Rybelsus evidenced higher semaglutide levels in 17 of the 19 blood draws taken until the 24-hour completion of the study averaging 18.8% higher semaglutide levels over the course of the study compared to Rybelsus alone, although the differences were variable and not significant statistically with such a small sample size. The two arms of the Study being reported today compared equal 7 mg semaglutide doses from a Rybelsus swallowed tablet versus a DehydraTECH-processed Rybelsus swallowed capsule. The volunteers in this Study were administered the drugs while they were in a "fed" state, as compared to an earlier study that demonstrated a 43% peak blood level improvement wherein the volunteers were administered the drug in a "fasted" state. It should be noted that Novo Nordisk, the owner and manufacturer of Rybelsus, recommends taking Rybelsus on an empty stomach, because studies have shown that Rybelsus administration under fed conditions leads to decreased systemic absorption. Their label reads, "Take RYBELSUS by mouth on an empty stomach when you first wake up with a sip of plain water." Next steps moving forward in Lexaria's 2024 GLP-1 experimental program will include finalization of our ongoing animal study, which has already produced positive results as previously announced, and continued progress toward initiation of our planned upcoming 12-week chronic human study, which will be conducted under fasted dosing conditions. Data from the tolerability evaluations and the mouth melt absorption Study arm will also be available soon.

09:23 EDT Vera Bradley teams with Urban Outfitters to launch vintage-inspired collection - Vera Bradley (VRA) and "its iconic American bag, luggage, and lifestyle brand, Vera Bradley," have collaborated with lifestyle retailer Urban Outfitters (URBN) to launch a vintage-inspired capsule collection. The exclusive collection features six thoughtfully designed re-editions of some of Vera Bradley's most popular styles: the Vintage Tote, Molly Shoulder Bag, Vintage Duffel, Charm. Each item showcases three new patterns that evoke etc....Vera Bradley's storied past-Daisy Ditsy Goji Berry etc. ,bringing a nostalgic touch to contemporary fashion. ...Our collaboration with Vera Bradley perfectly embodies this mission, blending functional, vintage-inspired designs with the signature style that resonates with Gen Z. This launch is just the start, and we're excited about the future possibilities for both of our brands," commented Shea Jensen, President, Urban Outfitters. The collection styles range in price from $15 to $100. Shop the collection now at select Urban Outfitters stores and online at www.urbanoutfitters.com. Follow @verabradley and @urbanoutfitters for updates and to learn more about additional future product drops later this year.

09:20 EDT Kerrisdale Capital short Lumen Technologies, says AI will not 'fix this mess' - In a recently published report titled "AI-N't Gonna Fix This Mess," Kerrisdale Capital said it is short shares of Lumen Technologies, "a $26B telecommunications company trying to spin how AI will fuel the dramatic turnaround of a secularly declining business saddled with $19B of debt." "In recent weeks, a mixture of buzzy headlines, misplaced retail investor enthusiasm, and short covering has sent a previously moribund stock soaring 400%... We understand the allure of trying to find the next great AI play, but at these levels, an investment in Lumen lacks more than just artificial intelligence," the report reads. Kerrisdale says "don't buy the AI hype," the $5B in custom networks is "only slightly over $1 per share of value," and the $7B in AI sales opportunities is a "pipedream." Shares of Lumen are down over 6% in pre-market trading. Reference Link

09:19 EDT Nuwellis publishes study on reduction of heart failure readmissions with Aquadex - Nuwellis announces the publication of a new study in Current Problems in Cardiology demonstrating the effectiveness of Aquadex ultrafiltration therapy in reducing 60 day hospital readmission rates for patients with acutely decompensated heart failure or ADHF, who are otherwise resistant to diuretic treatment. Significant Volume Loss and Weight Reduction: Patients experienced significant volume loss and weight reduction without adverse renal effects. Significant Reduction in Heart Failure Readmissions: The study found a statistically significant reduction in rehospitalization rates for heart failure at 60 days from the initiation of ultrafiltration therapy compared to the pre-ultrafiltration period..."This study underscores the value of ultrafiltration therapy with Aquadex in managing fluid overload in hospitalized heart failure patients," commented Nestor Jaramillo, President and CEO of Nuwellis. "The positive outcomes reported in this community-based hospital setting demonstrate the broader applicability and effectiveness of Aquadex, which is critical as we continue to expand access to this life-saving therapy in multiple academic and community healthcare centers across the country." Mr. Jaramillo added, "These study results should be of interest to the many physicians and hospital administrators seeking to reduce the losses associated with heart failure patient care. The statistically significant outcomes reported in this study further reinforce the value of Aquadex. This new evidence comes as we marked 30% revenue growth in our core business, as reported in our second quarter earnings release."

09:18 EDT Illumina's cancer biomarker test approved by FDA - Illumina announced FDA approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions that may benefit from treatment with Bayer's Vitrakvi. The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection fusion-positive non-small-cell lung cancer that may benefit from treatment with Lilly's Retevmo. TSO Comprehensive will begin shipping to customers this year. A separate CE-marked version of TSO Comprehensive is already available in Europe, launched in 2022.

09:16 EDT Definitive Healthcare expands Population Intelligence platform - Definitive Healthcare announced the expansion of its Population Intelligence platform to a broader range of industries selling into healthcare. Building on its success in offering healthcare provider organizations patient and consumer analytics, Population Intelligence now supports businesses in additional sectors-such as advertising, marketing, telehealth, staffing, and medical supply-to drive stronger performance for marketing campaigns and digital advertising. Population Intelligence combines robust clinical and consumer data to create a powerful tool for precision marketing. With data on 250+ million unique consumers aged 18+ and over, 300 clinical propensity, social determinants of health, and media channel models, businesses can identify consumers who are most likely to have a specific condition or need certain healthcare services. This allows organizations to create more precise audience segments and launch highly targeted marketing campaigns, driving more efficient consumer activation.

09:09 EDT Armlogi announces warehouse at Port of Savannah is fully operational - Armlogi Holding announced that its newly expanded warehouse at the Port of Savannah, referred to as "SAV1", is now fully operational. This facility has rapidly become the busiest among Armlogi's portfolio of 11 warehouses nationwide. Since its launch in June 2024, SAV1 has handled over 800 container shipments, with an additional 300 containers expected soon. The rapid scale of operations highlights the importance of the Port of Savannah in Armlogi's logistics network and underscores the Company's robust capacity for handling large volumes of goods. Just weeks after opening, the warehouse has over 70% occupancy, demonstrating significant demand and utilization. SAV1 is equipped with logistics technology and is designed to support a wide range of supply chain activities, from storage and distribution to complex logistics solutions. Its strategic location at one of the busiest ports in the United States provides optimal access for importers and exporters, further enhancing Armlogi's service offerings.

09:08 EDT Broadcom announces VMware Tanzu Platform 10 - Broadcom announced VMware Tanzu Platform 10, a cloud native application platform that accelerates software delivery, providing platform engineering teams enhanced governance and operational efficiency while reducing toil and complexity for development teams. The company also introduced Tanzu AI Solutions, a set of capabilities within Tanzu Platform that help application teams deliver GenAI-powered, intelligent applications quickly, safely, and at scale. Tanzu Platform 10 and VMware Cloud Foundation now provide the fastest path to a complete private cloud with a self-configuring setup experience and support for air-gapped environments.

09:08 EDT Neuraxis: Geisinger medical policy coverage for PENFS, effective September 15 - NeurAxis announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation PENFS for Geisinger Health Plan, serving 600,000+ enrollees in central Pennsylvania. This medical policy will bring our national total coverage for PENFS to roughly 24 million insured lives, with more decisions from major payers still pending..."We are excited about the coverage expansion with Geisinger Health, an affiliate of the Geisinger Janet Weis Children's Hospital, located in central Pennsylvania," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "We continue to make progress in our commercialization of IB-Stim by increasing payer coverage to drive market adoption of our technology. Payers' acceptance of our PENFS technology is the result of the robust body of published research. We are on track to achieve our stated goal of having medical policy coverage for at least 50M lives by the end of 2024, which will set the stage for a significant revenue and margin ramp in late 2024 and into 2025," Carrico noted...

09:07 EDT Heramba Electric wins $26M e-mobility contract in Seattle, Washington area - Heramba Electric's wholly-owned subsidiary Kiepe Electric has been awarded a $26M battery upgrade program by King County Metro in Seattle, Washington for enhanced In Motion Charging on its electric trolley buses. The three-year agreement will ensure enhanced in-motion charging capability for electric trolley buses and provide King County with upgraded battery packs that will deliver approximately three times the capacity of the original energy storage system. Kiepe will also provide on-site service support for up to five years, starting in 2024.

09:05 EDT Markforged announces FX10 Metal Kit print engine - Markforged Holding announced the FX10 Metal Kit, a print engine that brings metal printing capability to the FX10. With this kit, the FX10 becomes the world's first industrial 3D printer that can print both metal filaments and composites with continuous fiber reinforcement.

09:03 EDT Abbott expands Pure Bliss line of infant formulas - Abbott announced the expansion of its Pure Bliss by Similac line of organic, and European-made infant formulas. Pure Bliss by Similac offers specific sourcing of ingredients. The Pure Bliss line includes the following: Pure Bliss by Similac Irish Farms infant formula is made in Ireland with fresh milk sourced from Irish farms where cows feed in grassy pastures much of the year. Irish Farms formula is exclusively produced at Abbott's manufacturing facility in Ireland and is imported to the U.S. Pure Bliss by Similac Organic infant formula is a USDA-certified organic formula. Pure Bliss by Similac Organic with A2 Milk infant formula is a USDA-certified organic formula using milk from select cows that produce A2 beta-caseini protein, which is naturally easy to digestii and more like the protein found in breast milk.

09:02 EDT Progress Software announces latest release of Progress Semaphore - Progress announced the latest release of Progress Semaphore, its metadata management and semantic AI platform. Building on existing knowledge management capabilities, the Semaphore 5.10 platform release introduces intuitive AI-assisted knowledge modeling, extended mapping capabilities and classification filtering to enhance user productivity and simplify the knowledge management experience. What is new in Semaphore 5.10: AI Model Builder: Built to prioritize user productivity, the AI Model Builder is an AI-powered tool that simplifies the knowledge modeling experience. Powered by large language models (LLMs), the AI Model Builder accelerates the creation and enrichment of semantic knowledge models. Users can now create better semantic models more efficiently by starting with a seed concept and enhancing existing models with specific concepts or alternative labels. This feature empowers business experts to delve deeper into data, streamlining decision-making processes. Filtering of Classification Results by Publish Set: For improved collaboration, Semaphore 5.10 allows the same Classification Server instance to be shared across different project groups. This enables more efficient filtering and viewing of classification results from team projects. Different models with varying data sets can coexist within the same Classification Server instance, displaying results based on user-specified criteria. Mapping Relations Within the Current Model: Effective decision-making depends on reliable information and quality data. By creating mapping relations within current knowledge models, Semaphore 5.10 enables the capture of similarities between models and the formation of mapping relationships. Users gain insights into how the different pieces fit together and facilitate knowledge sharing across the organization. Easy Import and Export of Shapes Constraint Language: Using SHACL enhances data quality and consistency by defining rules and validations for data models. Semaphore 5.10 introduces a user-friendly interface for importing and exporting SHACL. This feature streamlines processes, reduces time to value and makes custom SHACL easier to use.

08:58 EDT Delcath Systems announces outcomes from independent study on PHP - Delcath Systems announced the publication of a retrospective study by independent investigators in the Annals of Surgical Oncology. The study, titled "Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion, PHP, as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma," was conducted by researchers at Moffitt Cancer Center in Tampa, Florida. The 30-patient study reported that Delcath's HEPZATO KIT provided better disease control in the liver and improved progression-free survival in patients with hepatic metastases from uveal melanoma, compared to both immunotherapy and other liver-directed therapies.

08:52 EDT Mawson Infrastructure announces expansion of lease in Phio - Mawson Infrastructure Group announced its expansion of its lease in Ohio, further extending its AI and HPC growth capacities. Mawson also invites additional AI/HPC partners, as it expects to further increase its total capacity from the currently operational 129 megawatts across its Pennsylvania facilities in Midland, PA and Bellefonte, PA, to about 153 MW, given its expansion to Ohio. Key Highlights: Mawson's expansion into Perry County, Ohio further increases its footprint in the PJM market, which is the largest wholesale electric market in North America and has competitive power rates and is a deregulated market. Secures lease amendment for an extended term for 9 years through April 2033. Secures initial 24 megawatts of capacity through agreements, which could grow Mawson from currently operational 129 MW to 153 MW. Expected to commence initial construction while inviting AI/HPC partners to discuss opportunities to partner and collaborate with Mawson to power the deployment of NVIDIA GPUs and other high performance and accelerated computing.

08:48 EDT Nextech3D.AI launches new features for Aritize3D platform - Nextech3D.AI announced key new features for its gen AI powered Aritize3D platform that enhance product experiences and make it easier for customers to visualize 3D models. The launch of these new platform features, are designed to enhance the shopping experience for its customers and their end users. The company, a leader in generative AI-powered 3D technology for e-commerce, is continuing to innovate and expand it's platform and 3D modeling solutions. Key updates include: Dimension View for 3D Models: Users can now view the dimensions of 3D models directly within the platform, providing critical information for better purchasing and design decisions. Customizable QR Codes: Customers can create branded QR codes for their 3D models, enhancing brand visibility across marketing materials, physical stores, and online platforms. Integration with Multiple 3D Model Viewers: The platform now supports three different 3D model viewers, offering flexibility to meet diverse customer needs.

08:46 EDT Consolidated Water increases dividend and declares Q4 11c cash dividend - Consolidated Water has increased its quarterly cash dividend and declared a dividend of 11c per share for the fourth quarter of 2024. This fourth quarter dividend represents an increase of 15.8% from the third quarter 2024 dividend of 9.5c per share. The cash dividend is payable on October 31 to shareholders of record at the close of business on October 1. "Improving sales from our Caribbean-based businesses and the resolution of our Mexico arbitration have resulted in increased cash flow," stated Consolidated Water president and CEO, Rick McTaggart. "These results and our strong positive outlook supported the decision by our board of directors to increase our quarterly dividend for our stockholders." The company also recently reported revenue of $32.5M and earnings per share of 99c in the second quarter of 2024.

08:44 EDT Sparta Commercial Services announces official launch of EZBroker360 - Sparta Commercial Services announced the official launch of its product, EZBroker360, operated by the Company's subsidiary, Agoge Global USA. The event, hosted by Sparta's joint-venture partner, Wedev Group Ltda., in the heart of Brazil's "Silicon Valley," provided the perfect stage for Sparta to introduce this innovative solution to a diverse audience of startups, investors, and industry leaders. EZBroker360 is designed to revolutionize the financial management of Brazilian importers and exporters by combining a Merchant of Record model with a comprehensive suite of services. This includes seamless integration of invoice management, bill of lading, and import/export declarations, along with a robust staged financing module.

08:42 EDT American Rebel names James Porter as president, American Rebel Beverages - American Rebel Holdings announces the appointment of James "Todd" Porter to serve as President of American Rebel Beverages, LLC; a wholly-owned subsidiary of American Rebel Holdings. Mr. Porter will be leading the consumer product beverage division, based in the Nashville, Tennessee metro area, assuming P&L responsibility in addition to spearheading the division's manufacturing, sales and marketing and strategic growth strategy including additional beverage production extensions that align with America's Patriotic Brand - American Rebel. Porter most recently served as the General Manager of Veterans United Craft Brewery, an independent veteran-owned brewery based in Jacksonville gaining valuable experience related to the production and manufacturing of beer from overseeing the day-to-day operations

08:41 EDT Nasdaq files with SEC to list, trade Nasdaq Bitcoin Index Options - Nasdaq, in partnership with CF Benchmarks, announced its filing with the Securities and Exchange Commission to list and trade Nasdaq Bitcoin Index Options. Upon regulatory approval, investors will be able to manage positions and hedge investments in cryptocurrency through options, furthering the maturity and liquidity of the asset class. Pending regulatory approval, the index options will track the price of Bitcoin as represented by the CME CF Bitcoin Real-Time Index. The product is intended to provide institutional and retail market participants access to an important risk management tool. The calculations powering the index are executed every second of every day by aggregating Bitcoin-USD order data from the leading cryptocurrency exchanges meeting the specific criteria.

08:38 EDT Nano Nuclear Energy appoints Terry Robling as chair of Advisory Board - NANO Nuclear Energy has appointed Lieutenant General Terry G. Robling, USMC, as the Chair of its Executive Advisory Board for Federal and Defense Appropriations and Requirements. Lieutenant General Robling's 38 years of distinguished service in the United States Marine Corps earned him 31 Department of Defense commendations, including the Order of the Rising Sun from the Emperor of Japan and the Legion of Honour from the President of France. A three-star general officer, Lt. Gen. Robling culminated his military career as the Commanding General of U.S. Marine Corps Forces, Pacific, where he oversaw all Marine Corps operations in the strategically vital Asia-Pacific region.

08:37 EDT ECD Automotive Design enters licensing agreement with Blackbridge Motors - ECD Automotive Design announced that it entered into a licensing agreement with Blackbridge Motors to produce branded classic Land Rover Defender SUVs at their Kissimmee, FL facility. The license agreement provides ECD access to Blackbridge's IP, branding and top-of-funnel marketing support in exchange for a fee and royalty per vehicle sale. Blackbridge Motors is a resto-mod producer of classic Land Rover Defenders that blend heritage style and modern performance.

08:35 EDT Worlds Inc. partners with Jordan Freeman Group - ZOOM Platform - Worlds has closed on the agreement with Jordan Freeman Group - ZOOM Platform to license the ZOOM Platform DRM-Free online entertainment platform and portfolio of classic video games, including upcoming original intellectual properties, such as Shadow Stalkers and MegaRace: DeathMatch. The agreement also includes licensing Wanderful Interactive intellectual properties, originally published as Living Books, based on the works of award-winning authors including Marc Brown, Dr. Seuss, Mercer Mayer, Stan & Jan Berenstain, and other popular children's book authors.

08:34 EDT Zai Lab announced data from Phase 1 study of ZL-1218 - Zai Lab announced that data from a Phase 1 study of ZL-1218, the company's anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology, ESMO, Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escalation clinical trial will highlight the potential of ZL-1218 to reduce regulatory T cells and modulate T-cell function in the tumor microenvironment, TME, of advanced solid tumors. "The ability to overcome the complexities of the tumor microenvironment are critical to improving patient outcomes in cancer immunotherapy," said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. "The reduction of suppressive tumor-associated regulatory T cells by ZL-1218 offers promise to re-stimulate the immune attack on advanced solid tumors. We look forward to sharing preliminary results from our Phase 1 study at ESMO 2024."

08:32 EDT Femasys hosts Congresswoman Lucy McBath at Georgia headquarters - Femasys hosted Congresswoman Lucy McBath, Georgia's 7th district representative to the U.S. House of Representatives, for an informative tour of the Company's facility headquartered in Suwanee, Georgia. Femasys Founder, President and CEO Kathy Lee-Sepsick said, "Women's reproductive health continues to be underserved and underfunded across the country. We are encouraged by the continued dialogue with leaders like Congresswoman McBath around our improved solutions for accessible, effective, and affordable reproductive health options for women. We look forward to continued visits and new and extended conversations with stakeholders across government, healthcare, and advocates as we continue to push for better and less-invasive options for women in their reproductive journeys."

08:31 EDT Janover launches Janover Pro subscription-based service - Janover announced the launch of Janover Pro, an innovative subscription-based service that provides users access to a rich and dynamic dataset of commercial lenders through Janover's user interface. Additionally, the Company announces that it has signed up its first Janover Pro subscriber. Janover Pro offers unparalleled access to a vast network of multifamily, commercial property, and SBA lenders, including more than 10% of all U.S. banks, 35% of the top 100 credit unions, and over 1,000 additional commercial lenders. This comprehensive data set features major products such as Fannie Mae, Freddie Mac, FHA, CMBS, life companies, debt funds, and a diverse range of other loan products and lenders. More importantly, it features banks and credit unions from every corner of the nation, with lenders directly providing first-party data to the platform which is regularly updated. Janover Pro provides detailed lender and originator credit box information and contact details, equipping users with the same tools and resources used by Janover's professional advisors. This enables them to compete with the biggest names in the industry like JLL, Walker & Dunlop, CBRE and beyond. The service is generally available on a 3-year subscription basis, providing continuous updates and access to the latest lender information with many additional features planned that the Janover Capital Markets team already uses.

08:28 EDT PaxMedica reports first patient treated with PAX-101 for HAT - PaxMedica announced a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense strain of Human African Trypanosomiasis is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi, and many East African countries, in preventing death due to this parasite, when used in the early or first stage of the infection.

08:27 EDT First Busey, CrossFirst enter plan of merger for $916.8M transaction - First Busey Corporation (BUSE) and CrossFirst Bankshares, (CFB) the signing of a definitive agreement and plan of merger, pursuant to which CrossFirst will merge with and into Busey in an all-common stock transaction valued at approximately $916.8 million, based on Busey's closing stock price of $27.39 as of August 26, 2024. The combined company, which will operate under the Busey brand, will have approximately $20 billion in total assets, approximately $17 billion in total deposits and approximately $13 billion in wealth management assets under care. The merger has been unanimously approved by each company's board of directors. In the merger, CrossFirst shareholders will receive 0.6675 shares of Busey common stock for each share held of CrossFirst common stock. CrossFirst's common shareholders, which currently do not receive a dividend, will be eligible to receive Busey's ongoing dividends as declared following the closing of the merger. Upon completion of the transaction, Busey's shareholders will own approximately 63.5% of the combined company and CrossFirst's shareholders will own approximately 36.5% of the combined company, on a fully-diluted basis, which will continue to trade on the Nasdaq under the "BUSE" stock ticker symbol. Completion of the merger is subject to customary closing conditions, including the approval of both Busey and CrossFirst shareholders and the regulatory approvals for the holding company merger and the bank merger. With approvals, the parties expect to close the holding company merger in the first or second quarter of 2025.

08:25 EDT VCI Global CEO, Dato' Victor Hoo, boosts shareholding by 15.27% - VCI Global Limited announces that its Chief Executive Officer, Dato' Victor Hoo, has significantly increased his shareholding in the Company. This move, along with the recent share buyback program announced on August 19, 2024, and the Company's strong financial performance for the first half of 2024...Prior to the transaction, Dato' Victor Hoo beneficially owned and controlled 12.05% of the Company's total outstanding shares, comprising 10.72% held directly and 1.33% of indirect shareholding through V Invesco Fund Limited, a company he owns. Following the transaction, he now beneficially owns and controls a total of approximately 27.32% of the Company's total outstanding shares. This represents an increase of 15.27% in his overall shareholding, underscoring his strong confidence in the Company's strategic direction and future growth potential. "I am deeply committed to VCI Global and its vision for long-term growth. My increased investment is a clear endorsement of the Company's direction and performance. Alongside our strong financial results and share buyback program, it reinforces my confidence in our continued success and our ability to deliver lasting value to shareholders," said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

08:24 EDT Mattel's Fisher-Price, John Legend partner to release covers of three songs - Fisher-Price and John Legend are officially partnering to release covers of three Fisher-Price songs: "Maybe," "Friendship," and "Great, Great Day." These songs, heard in both new and fan-favorite Fisher-Price toys, will be featured on Legend's debut Children's Album - My Favorite Dream - out this Friday, August 30 via Republic Records: Kids & Family.

08:23 EDT Ocean Biomedical: Dr. Jonathan Kurtis, MD issued patent for malaria treatment - Ocean Biomedical announced that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP...This patent is adding to Ocean Biomedical's global patent portfolio of over 5 dozen patents for discoveries with potential to impact major unmet medical needs in infectious disease, oncology, and fibrosis, developed through grants totaling over $125M. Kurtis' novel approach causes parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This patent expands protection for Dr. Kurtis' novel discoveries at ...a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs"The resurgence of Falciparum malaria worldwide is increasingly alarming and we are pleased to see Dr. Kurtis' work receive this patent coverage for such an important discovery. We will work hard to accelerate the development of our novel vaccine candidate and this novel class of antimalarial antibodies to get a new treatment option for severe malaria available as soon as possible," said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman.

08:21 EDT AtriCure announces first patient treated with AtriClip FLEX-Mini device - AtriCure announced that the first patient was treated with the AtriClip FLEX-Mini device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of AtriCure's AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for physicians.

08:20 EDT Carlyle Credit Income announces private placement of convertible preferred share - Carlyle Credit Income Fund has entered into a Purchase Agreement with certain institutional investors for the purchase and sale of approximately 11,517 shares of the Fund's 7.125% Series B Convertible Preferred Shares due August 2029, liquidation preference $1,000.00 per share. The Fund expects to receive net proceeds from the sale of the Convertible Preferred Shares of approximately $10.6 million. The offering is expected to close on or about August 27, 2024, subject to the satisfaction of customary closing conditions. The Convertible Preferred Shares pay a quarterly dividend at a fixed annual rate of 7.125% of the liquidation preference, or $71.25 per share, per year. The Fund is required to redeem, out of funds legally available therefor, all outstanding Convertible Preferred Shares on August 27, 2029, or the "Term Redemption Date," at a price equal to the liquidation preference plus an amount equal to accumulated but unpaid dividends and distributions, if any, on such shares to, but excluding, the Term Redemption Date. At any time on or after February 27, 2025, at the Fund's sole option, the Fund may redeem, from time to time, the Convertible Preferred Shares in whole or in part, out of funds legally available for such redemption, at a price per share equal to the sum of the liquidation preference plus an amount equal to accumulated but unpaid dividends, if any, on such shares to, but excluding, the date fixed for such redemption.

08:19 EDT Hims & Hers slips after Lilly says discount Zepbound single-dose vials available - Shares of Hims & Hers (HIMS) are down about 5% to $15.29 in early trading after Eli Lilly (LLY) announced Zepbound 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand. "The single-dose vials are priced at a 50% or greater discount compared to the list price of all other incretin, or GLP-1, medicines for obesity," Lilly stated earlier. In December of 2023, Hims & Hers Health unveiled "Weight Loss by Hims & Hers," which it called "a comprehensive and customizable clinical approach specifically designed to help people achieve their individual weight-loss goals." While recently initiating coverage of Hims & Hers with a Buy rating and $24 price target, Needham noted that while the stock has seen an increased level of volatility in association with its launch into the compounded GLP-1 space, the firm believes "this will have a more positive than negative impact" on the company's fundamental profile. Hims is "not just a GLP-1 story" as even without contribution from GLP-1, it is growing 40%-plus at over $1B in revenue and boasts multiple levers for growth and margin expansion, Needham added.

08:18 EDT Predictive Oncology study validates drug response data, enabling AI modeling - Predictive Oncology announced the results of a successful study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples stored within the Company's proprietary biobank. These samples had originally been tested and cryopreserved between 2008 and 2016. Concordance of drug response results between the original fresh patient sample testing and long-term cryogenically stored tumor material from the same patient was 100%. "We are extremely pleased with the results ofpoai this study, which demonstrates that even after an extended period of time - some as long as 16 years - the samples cryopreserved in our biobank remain viable and able to deliver the same drug response data as when originally tested," said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology. "This not only validates the utility of our biobank, but also the strength and reliability of the drug response data that we compiled over those many years. We are uniquely positioned to enable drug developers to query patient responses to their drug candidates, accounting for real-world patient heterogeneity, and to validate targets and biomarkers long before human clinical trials commence."

08:17 EDT Altria Group, NJOY respond to ITC determination in complaing against NJOY - Altria Group and its operating company NJOY respond to the U.S. International Trade Commission, ITC, Administrative Law Judge's, ALJ, initial determination regarding the patent infringement complaint JUUL Labs, JUUL, filed against NJOY. Last week, the ALJ provided notice of her initial determination supporting JUUL's allegations in its complaint and recommending an exclusion order that would prohibit the importation of NJOY ACE into the United States. Altria and NJOY respectfully disagree with the ALJ's initial determination, and NJOY looks forward to presenting its position to the full ITC, which is expected to issue a final decision by December 23, 2024.

08:15 EDT Ouster's Blue City achieves NEMA TS2 certification for safe traffic control - Ouster announced that its Blue City traffic management solution successfully passed the requirements of NEMA TS2 as a detection system for traffic actuation. "We are excited to announce that Blue City is the first NEMA TS2 certified solution with Buy America certified lidar. This is a testament to the quality and reliability of Ouster's products," said Asad Lesani, Ouster's VP for Smart Infrastructure Products. "Smart traffic solutions offer an immense opportunity to improve roadway efficiency, carbon emissions, and safety for all road users. Ouster's software-attached sales have continued to grow, and the NEMA TS2 certification will only further accelerate Blue City's adoption in cities across North America."

08:14 EDT Humacyte presents long-term results of ATEV in vascular trauma - Humacyte presented long-term results from a humanitarian program conducted in Ukraine under which the investigational acellular tissue engineered vessel was used to treat vascular injuries suffered during the ongoing conflict. Long-term follow-up results were presented for the first time and showed high rates of patency and the avoidance of amputation and infection despite the severe nature of the wartime injuries treated. The results were presented at the Military Health System Research Symposium, the U.S. Department of Defense's foremost scientific meeting, held in Kissimmee, Florida. The presentation highlighted the results for 16 extremity patients treated in Ukraine who provided consent for use of their results, a set of data known as the "V017 trial." The primary analyses for the V017 trial were at 30 days of follow up, and as previously reported the rate of success for treatment of patients with the ATEV at this time point was high with primary and secondary patency of 93.8%, zero amputations, and zero cases of infection of the ATEV. Longer-term results for the V017 patients were presented for the first time at the MHSRS meeting, with a mean follow-up duration of 357.9 days. Kaplan-Meier estimates of 12-month primary and secondary patency both were 87.1%. There were no instances of ATEV infections, amputation of affected limbs, or deaths related to ATEV through the end of long-term follow-up. There was one event of ATEV thrombosis after month six. There were no reports of ATEV aneurysm or pseudo-aneurysm. These results were achieved despite the fact that all patients had a high risk of wound infection and were severely injured, with a mean Injury Severity Score (ISS) of 20.1. Patients treated with the ATEV included those injured due to mine blasts, shrapnel and high velocity ballistics.

08:12 EDT Golden Heaven granted plot in China for amusement complex - Golden Heaven was granted the land use rights for an approximately 26,000-square-meter plot located in Yunhe Sanwan Scenic Spot in Yangzhou, Jiangsu Province, China on August 16 by Yangzhou Lemandi Tourism Development. The company plans to launch a new recreation and amusement complex at this site, with commercial operations anticipated to begin in October. By securing the land use rights in a tourist attraction of historical and cultural importance, as well as a location with high foot traffic, the company anticipates growth opportunities to be derived from introducing innovative amusement rides.

08:10 EDT CVS Health's Aetna to expand and simplify access to fertility services - Aetna, a CVS Health company, now offers intrauterine insemination as a medical benefit for eligible plans. Members may access this benefit as a test of fertility and, in some cases, to increase the chances of pregnancy. Aetna's landmark policy change increases access to family-building possibilities, regardless of sexual orientation or partner status.

08:09 EDT First Busey and CrossFirst to merge in $916.8M all stock deal - First Busey Corporation BUSE), the holding company for Busey Bank, and CrossFirst Bankshares or CrossFirst (CFB), the holding company for CrossFirst Bank, jointly announced today the signing of a definitive agreement and plan of merger, pursuant to which CrossFirst will merge with and into Busey in an all-common stock transaction valued at approximately $916.8M based on Busey's closing stock price of $27.39 as of August 26. The combined company, which will operate under the Busey brand, will have approximately $20B in total assets, approximately $17B in total deposits and approximately $13B in wealth management assets under care. "The partnership between our high-quality franchises is a great fit from a strategic, financial and cultural perspective, and we look forward to capitalizing on the many opportunities we see as a combined company in 2025 and beyond," said Busey Chairman and CEO Van Dukeman. "CrossFirst is a natural fit alongside Busey's established commercial and wealth management offerings and our payment technology solutions business, FirsTech, Inc. By leveraging CrossFirst's established presence in attractive markets with compelling growth potential, this partnership is expected to serve as a catalyst for additional commercial banking growth as well as expanded opportunities to grow our existing wealth management and payments businesses. We are excited for our associates, customers and shareholders to experience our next chapter as Busey and CrossFirst combine to form a premier commercial bank that maintains the community bank values our customers and communities expect and deserve." In the merger, CrossFirst shareholders will receive 0.6675 shares of Busey common stock for each share held of CrossFirst common stock. CrossFirst's common shareholders, which currently do not receive a dividend, will be eligible to receive Busey's ongoing dividends as declared following the closing of the merger.

08:09 EDT Centessa to present non-human primate data for ORX142 at Sleep Europe 2024 - Centessa Pharmaceuticals announced that preclinical data from a non-human primate study of ORX142, a highly potent and selective orexin receptor 2 agonist being developed to address excessive daytime sleepiness in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society being held September 24-27, 2024, in Seville, Spain. The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model. "ORX142 is the second drug candidate from our growing pipeline of potentially best-in-class OX2R agonists that has shown significant activity in promoting wakefulness at very low doses in highly predictive and translational preclinical models," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "We believe these non-human primate data are compelling as they demonstrate the potential for ORX142, a highly potent and novel OX2R agonist, to alleviate excessive daytime sleepiness in select neurological, neurodegenerative, and psychiatric disorders with no significant loss of orexin. We are thrilled to be sharing these preclinical data in a late-breaking presentation at Sleep Europe 2024."

08:07 EDT Reviva to host KOL event on vocal biomarker data from RECOVER trial - Reviva Pharmaceuticals will host a virtual key opinion leader event on Wednesday, September 4, 2024 at 2:00 PM ET. The event will feature Brian Kirkpatrick, MD and Mark Opler, PhD, MPH, who will discuss the unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia, and application of speech latency as an objective vocal biomarker in schizophrenia clinical trials for evaluation of negative symptoms. The discussion will focus on reviewing results of the vocal biomarker data and their relationship to the primary efficacy endpoint and key efficacy secondary endpoints negative symptoms, social functioning, social cognition and CGI from brilaroxazine Phase 3 RECOVER-1 trial in schizophrenia.

08:06 EDT Spectral AI completes burn center enrollment for U.S. Burn Pivotal Study - Spectral AI announced the completion of adult and pediatric patient enrollment at U.S. burn centers for its U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company's DeepView System for burn indication. Using data from these burn center patients, the Company will pursue a De Novo classification from the U.S. Food and Drug Administration for use of the DeepView System in burn centers and expects to submit the request in the second quarter of 2025.

08:04 EDT Aspira Women's Health partners with Dorsata to create clinical workflow tool - Aspira Women's Health signed a definitive agreement with Dorsata. Under terms of the agreement, Aspira and Dorsata will work together in collaboration with medical leadership from a 250+ obstetrics and gynecology physician group to develop a custom care module to aid healthcare providers in the diagnosis, treatment, and care of patients with an adnexal mass. Once completed, the Module will be integrated into Dorsata's electronic medical records tool which is embedded in the clinical practices of its women's health clients. Not only will the Module help improve the quality and consistency of patient care, but it is also expected to aggregate rich and structured clinical data from a nationwide network of providers and patients.

08:04 EDT NV5 Global to acquire California Water Resources Group in 'accretive' deal - NV5 Global announced that it has reached a definitive agreement to acquire Weston Solutions' California Water Resources Group. Located in Carlsbad, CA, the Water Resources Group's approximately 20 employees provide mandated environmental regulatory compliance services related to ports, waterways, watersheds, and other aquatic environments for municipalities and other government agencies.The Water Resources Group will strengthen NV5's existing water infrastructure design and hydrospatial businesses, expanding NV5's water resources capabilities and bringing access to new clients and contracting opportunities. The acquisition will be a cash transaction and will be immediately accretive to NV5's earnings. NV5 expects to recognize the revenue from this acquisition by the late third quarter of 2024. "Water resources is a growing part of NV5's business, with NV5 delivering engineering design, environmental compliance, surveying, and geospatial services for water delivery, wastewater, stormwater, coastal resilience, and marine infrastructure," said Dickerson Wright, PE, Executive Chairman at NV5. "Demand for compliance services in the water industry is growing rapidly due to expansion of the nation's water infrastructure and stringent regulatory requirements, and the acquisition of the California Water Resources group will assist us in meeting the growing demand for these services."

08:02 EDT BAIYU Holdings to acquire energy storage and lithium battery company - BAIYU Holdings, through its wholly owned subsidiary Shenzhen Baiyu Jucheng Data, has entered into a definitive share purchase agreement (on August 21 with Shenzhen Jintongyuan Energy Storage, a tech enterprise specializing in the R&D and production of high-performance energy storage batteries in China. This acquisition marks the company's strategy to expand into the renewable energy storage battery market. BAIYU agrees to acquire 100% of the equity interest of Jintongyuan for a total cash consideration of approximately $105M, payable in installments. Closing is expected to occur in or around September 2024.

07:44 EDT Archrock announces expiration of HSR Act waiting period for acqusition - Archrock announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with its pending acquisition of Total Operations and Production Services. The expiration of the waiting period under the HSR Act satisfies an important condition necessary for the completion of the transaction. The transaction is expected to close in the third quarter of 2024 subject to the satisfaction of other customary closing conditions.

07:43 EDT CERIS announces advancements to FWA solutions - CERIS has announced advancements to its current Fraud, Waste, and Abuse solutions, including earlier detection capabilities and improved behavioral analytics. These new integrations and services will expand on CERIS' current FWA offering for customers as they navigate a complex healthcare industry and work to better manage and mitigate prevalent fraud and risk issues in today's landscape. Through identity and behavioral analytics, scanners, dashboards, reporting, and FWA consulting, CERIS' enhanced solutions are automating detection and errors in billing to aid payers in prevention and remediation. The National Health Care Anti-Fraud Association estimates that financial losses for healthcare organizations are in the tens of billions of dollars each year. CERIS works closely with providers to overcome challenges and false payment methods through its FWA products. Today's enhancements will support the following: Fraud Case Analytics - SIU and Suspicious Activity Lead Services: Case data analytics will utilize client and industry data for rapid analysis and reporting through machine learning capabilities; Fraud Scanners: A suite of data scanners will detect suspicious activity on pre- and post-pay claims offering clients lead detection for Fraud, Waste & Abuse; Fraud Dashboard & Reporting: CERIS will offer flexible reporting options on client analysis and results through industry standard tools; FWA Consulting: CERIS will bring its expertise in prevention, remediation, and operational efficiencies of payment processing in support of Fraud, Waste & Abuse management

07:34 EDT Cosciens Biopharma says primary efficacy endpoint of DETECT-trial not met - Cosciens Biopharma announced the top-line results of its Phase 3 safety and efficacy study AEZS-130-P02, "the "DETECT-trial" evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency or "CGHD" . While top-line data show that macimorelin repeatedly demonstrated its capacity to stimulate growth hormone release as required to perform a growth hormone stimulation test, the primary efficacy endpoint for the DETECT-trial has not been met according to the definitions in the study protocol. In the study, the macimorelin test was compared to current standard growth hormone stimulation tests, arginine and clonidine .Although further analysis of the study results is required, initial review of the results indicates that the comparator tests may have led to a high false positive rate which impacted macimorelin's ability to reach the primary efficacy endpoint. These unexpected results require further clarification and some re-analyses with the aim to consider the trial outcome and the strategy moving forward..."The top-line results confirm the excellent safety of macimorelin, similar to what was demonstrated in our clinical and commercial experience with the use of macimorelin to diagnose adult growth hormone deficiency AGHD . However, it was surprising to see that many subjects, who had been adjudicated as ill or growth hormone deficient, according to the comparator tests arginine and clonidine, showed high growth hormone stimulation following macimorelin. Our team will be further analyzing the detailed data from the DETECT-trial to gain insights into the reasons behind these unexpected results" commented Nicola Ammer, Chief Medical Officer of the Company.

07:33 EDT Avant Brands announces 30-for-1 share consolidation - Avant Brands will consolidate its outstanding common shares on the basis of thirty existing common shares for one new common share of the Company. In accordance with the articles of the Company, the Consolidation has been approved by the board of directors of the Company, and shareholder approval is not required. The effective date for the Consolidation is Friday, August 30, 2024. As of the date of this news release, the Company has 316,342,373 common shares issued and outstanding. Following completion of the Consolidation, the Company is expected to have approximately 10,544,745 common shares issued and outstanding, subject to rounding. No fractional post-Consolidation common shares will be issued as a result of the Consolidation. The holdings of any shareholder who would otherwise be entitled to receive a fractional share as a result of the Consolidation shall be rounded up to the next higher whole number if the fraction is 0.5 or greater, and rounded down to the next lower whole number if the fraction is less than 0.5.

07:32 EDT Avicanna announces issuance of U.S. patent on topical technology - Avicanna announced the United States Patent and Trademark Office issuance of the Patent covering Avicanna's deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain. The patented technology demonstrated further significance through the results of real-world evidence study where the study participants self-reported improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation. The study saw seventy-one patients complete baseline testing and a follow up after one month including two standardized symptom questionnaires with demographic, medical history, medication use. The study evaluated patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% cannabidiol and 1% Cannabigerol on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural injuries, and post-surgical pain.

07:27 EDT Boston Scientific obtains CE mark for ACURATE Prime Aortic Valve System - Boston Scientific announced it has obtained CE mark for the ACURATE Prime Aortic Valve System, the newest transcatheter aortic valve replacement, TAVR, technology in the company's structural heart portfolio. The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2 platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

07:16 EDT Sealsq unveils advanced digital crypto wallet - SEALSQ Corp unveils advanced digital crypto wallet features designed to protect against the potential threats posed by quantum computing. These include a converged eSIM solution that integrates an embedded secure element, eUICC, and certified NFC connectivity into a single platform. SEALSQ is also collaborating on a proof-of-technology project with the Hedera blockchain, focused on integrating Public Key Infrastructure signatures with biometric authentication.

07:16 EDT Invivyd gives efficacy data from ongoing CANOPY trial of PEMGARDA for Covid-19 - Invivyd, announced positive 180-day exploratory clinical efficacy data from the company's ongoing CANOPY Phase 3 clinical trial of pemivibart, a half-life extended investigational monoclonal antibody or mAb for the pre-exposure prophylaxis or PrEP of COVID-19. The exploratory clinical efficacy data in Cohort B, a placebo-controlled cohort of all-comer immunocompetent individuals, showed a relative risk reduction of 84% with pemivibart compared to placebo in the likelihood of trial participants contracting confirmed symptomatic COVID-19, with no hospitalizations or deaths due to COVID-19 reported. Cohort B participants treated with pemivibart experienced a 1.9% rate of symptomatic COVID-19 across a 180-day time period, whereas Cohort B participants in the placebo arm experienced an 11.9% rate of symptomatic COVID-19, a robust attack rate for the trial. Cases of COVID-19 observed in the pemivibart arm were mild or moderate in severity...The 180-day clinical efficacy exploratory data announced complements the initial clinical efficacy exploratory data demonstrating potential signals of clinical protection from symptomatic COVID-19 shared previously. The company expects the full data set to be provided in an upcoming scientific publication. ..."The positive CANOPY clinical efficacy data through 6 months is encouraging and will be helpful to clinicians in making an informed decision about PEMGARDA use in their immunocompromised, at-risk patients, " said Cameron R. Wolfe, M.B.B.S., M.P.H., Professor of Medicine, Transplant Infectious Disease at Duke University School of Medicine. "The risk of COVID-19 for immunocompromised people remains disproportionate and having a mAb in the toolbox for pre-exposure prophylaxis is extremely beneficial."

07:15 EDT LightInTheBox appoints Yan as director, chairman - LightInTheBox Holding announced the appointment of Zhi Yan as a director to the board of directors of the Company and to succeed Jian He as the chairman of the Board, effective August 26, 2024. Following the Appointment, Jian He will remain as a director of the Board and the Chief Executive Officer of the Company.

07:13 EDT Silver Tiger Metals provides update on PFS drilling program on El Tigre - Silver Tiger Metals provided an update on the last remaining holes of the Company's Pre-Feasibility Study drilling program on its El Tigre Project in Sonora, Mexico. These new results are highlighting the near surface, consistent mineralization present. Drill hole ET-23-513 intersected the Stockwork Zone with 126.6 metres grading 0.77 g/t gold equivalent or 57.5 g/t silver equivalent from 7.4 to 134.0 metres, consisting of 0.55 g/t gold and 16.6 g/t silver INCLUDING 19.6 metres grading 1.68 g/t gold equivalent or 126.2 g/t silver equivalent from 94.0 to 113.6 metres, consisting of 1.03 g/t gold and 48.8 g/t silver. This hole highlights the confirms the strong, near-surface mineralization footprint of the Stockwork Zone and expands the Footwall Zone by 50 metres to the east over the 2023 MRE. New intersections through the Stockwork gold deposit, comprised of the Footwall, Hanging Wall and high-grade Keel Zones: Drill hole ET-23-531: 23.4 metres grading 1.30 g/t gold equivalent or 97.6 g/t silver equivalent from 121.4 to 144.8 metres, consisting of 0.29 g/t gold and 75.7 g/t silver INCLUDING 2.2 metres grading 11.75 g/t gold equivalent or 881.5 g/t silver equivalent from 140.0 to 142.2 metres consisting of 1.20 g/t gold and 791.4 g/t silver. The hole highlights the un-mined high-grade veins still present with the Stockwork Zone. Drill hole ET-23-555: 69.1 metres grading 0.73 g/t gold equivalent or 54.8 g/t silver equivalent from 79.9 to 149.0 metres, consisting of 0.57 g/t gold and 12.2 g/t silver INCLUDING 7.0 metres grading2.13 g/t gold equivalent or 160.0 g/t silver equivalent from 82.0 to 89.0 metres consisting of 2.12 g/t gold and 0.7 g/t silver. The hole confirms Hanging Wall Zone mineralization 200 metres south of Starter Pit and expands mineralization profile 25 metres to the west. Drill hole ET-23-562: 118.7 metres grading 0.51 g/t gold equivalent or 38.3 g/t silver equivalent from 55.9 to 174.6 metres, consisting of 0.46 g/t gold and 3.5 g/t silver INCLUDING 9.6 metres grading 1.18 g/t gold equivalent or 88.6 g/t silver equivalent from 165.0 to 174.6 metres consisting of 0.80 g/t gold and 28.3 g/t silver. The hole highlights the un-mined high-grade SK veins still present with the Stockwork Zone. Silver Tiger's CEO, Glenn Jessome, stated, "As we progress to a PFS in September 2024, this release marks the last of the promising drill results from the PFS Drilling Program" Mr. Jessome further stated, "These results further de-risk the project and, coupled with the advantageous geotechnical and metallurgical results, increase the confidence and size of the El Tigre Project."

07:12 EDT Events.com to go public on NYSE through Concord Acquisition Corp II combination

07:11 EDT Bitfarms announces assumption of control of Sharon, PA site - Bitfarms entered into the definitive lease agreement and has assumed control of its newest data center in Sharon, Pennsylvania, initially announced on June 13, 2024. This site represents Bitfarms' first mega-site in the U.S. with access to up to 120 MW. With this transaction, Bitfarms has closed on 110 MW, 30 of which are slated to come online by YE 2024. Bitfarms has also signed a Letter of Intent for a lease to an additional 10 MW site, which will bring total site capacity to 120 MW in 2025.

07:10 EDT Lifeist Wellness' Mikra engages impact.com for partnerships expansion - Lifeist Wellness reports that its U.S. biosciences subsidiary Mikra Cellular Sciences has engaged the services of impact.com to deploy their partnership discovery, management and optimization platform. Partnerships and affiliate marketing are a key area of growth in the nutraceutical industry, and Mikra is committed to dramatically expanding its footprint in that space.

07:09 EDT West Red Lake reports drill results from Madsen Mine - West Red Lake Gold Mines reports drill results from its 100% owned Madsen Mine located in the Red Lake Gold District of Northwestern Ontario, Canada. The drill results featured in this news release are focused on the high-grade Austin and McVeigh Zones. The Austin Zone currently contains an Indicated mineral resource of 914,200 ounces grading 6.9 grams per tonne gold, with an additional Inferred resource of 104,900 oz grading 6.5 g/t Au. The McVeigh Zone currently contains an Indicated mineral resource of 79,800 oz grading 6.4 g/t Au, with an additional Inferred resource of 14,300 oz grading 6.9 g/t Au. These results follow-up on the significant intercepts previously announced on August 12, 2024, where drilling returned 107.61 g/t Au over 2.5 meters at Austin and 106.99 g/t Au over 2.35m at McVeigh. The purpose of this drilling was definition within priority areas of Austin and McVeigh to continue building an inventory of high-confidence ounces to support the restart of production at the Madsen mine, which is expected to commence in H2 2025. The Company expects to complete a pre-feasibility study in support of that restart goal in the coming months. MCVEIGH ZONE HIGHLIGHTS: Hole MM24D-01-4081-025 Intersected 5.5m @ 17.77 g/t Au, from 44.5m to 50.0m, Including 2.2m @ 38.56 g/t Au, from 45.0m to 47.2m, Also Including 0.5m @ 19.15 g/t Au, from 49.5m to 50.0m. Hole MM24D-01-4081-028 Intersected 2m @ 36.62 g/t Au, from 51.5m to 53.5m, Including 0.6m @ 100.44 g/t Au, from 52.4m to 53.0m. Hole MM24D-01-4081-027 Intersected 5m @ 10.82 g/t Au, from 43m to 48m, Including 1m @ 11.44 g/t Au, from 44m to 45m, Also including 0.5m @ 64.71 g/t Au, from 46.6m to 47.1m. Hole MM24D-01-4081-039 Intersected 0.6m @ 89.93 g/t Au, from 50.0m to 50.6m. AUSTIN ZONE HIGHLIGHTS: Hole MM24D-09-4796-025 Intersected 12.12m @ 7.35 g/t Au, from 92.88m to 105.00m, Including 2.5m @ 19.39 g/t Au, from 93.5m to 96.0m. Hole MM24D-09-4796-023 Intersected 7m @ 11.06 g/t Au, from 85.5m to 92.5m, Including 0.51m @ 15.72 g/t Au, from 87.09m to 87.60m, Also including 1.87m @ 28.14 g/t Au, from 90.63m to 92.50m. Hole MM24D-09-4796-029 Intersected 6.3m @ 6.04 g/t Au, from 77.0m to 83.3m, Including 0.67m @ 13.82 g/t Au, from 78.00m to 78.67m, Also including 1m @ 12.60 g/t Au, from 82.3m to 83.3m. Shane Williams, President & CEO, stated, "The exceptional drill results that continue to be produced from McVeigh are very encouraging and highlight the opportunity that remains in this shallow, high-grade, easily accessible portion of the Madsen deposit. The Austin zone also continues to impress with solid results that help to strengthen our view that the Madsen deposit has plenty of meat left on the bones while also offering significant upside as we continue to access deeper portions of the main deposit."

07:07 EDT Lifezone Metals initiates process for risk insurance for project in Tanzania - Lifezone Metals Limited's (LZM) Chief Executive Officer, Chris Showalter announces that Lifezone has engaged in high-level discussions with U.S. and Tanzanian Government officials to further investment initiatives in critical minerals projects in Africa. The Kabanga Nickel Project, located in north-west Tanzania, is being advanced through a strategic partnership between Lifezone, the Government of Tanzania and BHP Group (BHP). Kabanga is believed to be one of the world's largest and highest-grade undeveloped nickel sulfide deposits. The Project is expected to establish first-of-its-kind nickel, copper and cobalt processing in Tanzania, delivering value addition and driving sustainable development for the benefit of Tanzania's citizens.

07:07 EDT Okyo granted U.S. patent covering OK-101's for DED treatment - OKYO Pharma Limited announced the grant of a key U.S. Patent No. 12,053,501 which issued on August 6th entitled: "Methods for Treating Symptoms of Dry Eye Disease". The present disclosure covers issued claims on OK-101's use to treat irritated, burning eyes and blurred vision in patients suffering from DED, strengthening the Company's intellectual property position in this field. "We are delighted with the issuance of this U.S. patent, which underscores the innovative potential of OK-101 to treat DED. This milestone strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement in addressing significant unmet medical needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. "The issuance of this patent further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation. The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates."

07:05 EDT CPI Card Group joins forces with Rippleshot - CPI Card Group announces a strategic relationship with Rippleshot to provide its fraud prevention services to CPI customers. Rippleshot leverages artificial intelligence, machine learning automation and predictive analytics to detect and prevent credit and debit card fraud. With the addition of Rippleshot, CPI customers can more effectively prevent fraudulent events before they occur and reduce the frustrations that epitomize the fraud management experience.

07:04 EDT Lyft and Payfare launch new features for Lyft card and app - Lyft (LYFT) and Payfare (PYFRF) are launching new features for the Lyft Direct debit card and banking app. Lyft Direct is a mobile banking solution designed for drivers on the Lyft platform which offers free instant access to earnings after every ride. The program also features a cashback rewards system, where drivers can save on everyday spending on essential items like fuel. This upgraded version of the financial management platform includes a range of features designed to enhance the financial well-being and overall health of Lyft Direct cardholders: drivers on the Lyft platform now have access to a high-yield savings account, and cardholders can now automatically add a portion of their earnings per ride to their savings account, helping them achieve their financial goals; qualifying cardholders can utilize Balance Protection, providing access to up to $200; elite drivers on the Lyft platform can save with 10% cashback on gas, 12% cashback on EV charging, and 5% cashback on dining; drivers on the Lyft platform can now take control of their personal budgets with Spend Insights; cardholders are now able to deposit cash to their Lyft Direct account at participating ATM locations.

06:53 EDT Descartes Systems' routing solution adopted by Brazil's Solar Coca-Cola - Descartes Systems announced that Solar Coca-Cola, the second largest manufacturer and distributor of Coca-Cola in Brazil, is using Descartes' route execution and fleet performance management solution to optimize the last mile delivery performance of 1,400+ drivers across 44 distribution centers and 13 production facilities serving an area that represents 70% of the country. Part of Descartes' routing, mobile and telematics solution suite, the Descartes route execution and fleet performance management solution helps retail food and beverage distribution companies, like Solar Coca-Cola, manage route execution for optimal efficiency and minimize the impact of unforeseen events on customer service levels, mileage and costs.

06:46 EDT Merck initiates Phase 3 trial of bomedemstat - Merck announced the initiation of Shorespan-007, a pivotal Phase 3 clinical trial evaluating bomedemstat, an investigational orally available lysine-specific demethylase 1 inhibitor, for the treatment of patients with essential thrombocythemia who have previously not received cytoreductive therapy. Essential thrombocythemia is a chronic, rare blood disorder and is the most common type of myeloproliferative neoplasm. Global recruitment of the Shorespan-007 trial has begun, with patients now enrolling.

06:37 EDT Cheer Holding granted patent in China for AI operation data management system - Cheer Holding's independently developed "An Intelligent Operation Data Management Method and System" has obtained the certificate of invention patent issued by the China National Intellectual Property Administration, and the company will accelerate the authorized use of the invention patent in the relevant industries. The invention relates to the field of artificial intelligence operation data management, including: obtaining the initial core data of all categories in the operation data of the current film and television platform, preprocessing the initial core data of all categories to obtain the final core data of each category, calculating the impact value of the final core data of each category, based on which obtaining the operation analysis matrix, based on which obtaining the operation judgment result of the current film and television platform, based on which obtaining the operation adjustment mode of the current film and television platform. It quantifies the impact of the final core data of each category on the operation of the platform, and determines the most effective operation adjustment method for improving the daily revenue from operation of the current film and television platform based on multiple influencing factors.

06:32 EDT Roche announces PiaSky approved in EU for people with PNH - Roche announced that the European Commission has approved PiaSky, a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents with paroxysmal nocturnal haemoglobinuria, or PNH, who are either new to, or have been previously treated with C5 inhibitors. "PiaSky is the first monthly subcutaneous treatment for PNH in the European Union, with the option to self-administer following adequate training. It provides an alternative option to current C5 inhibitors that require regular intravenous infusions, which could help to reduce treatment burden and disruption to the lives of people with PNH and their caregivers," the company stated.

06:19 EDT Flutter Entertainment-owned casino in Georgia charged $330M in copyright ruling - On August 20, the Court of First Instance in the country of Georgia ruled in favor of Aviator LLC's copyright and trademark infringement claim against gaming company Spribe Oundefined and Adjarabet, Georgia's largest online casino, owned by Flutter Entertainment. The court ruling found copyright and trademark infringement and invalidated trademark registrations based on bad faith registration and copyright infringement, awarding the claimant damages in the amount of $330M. Aviator LLC owns several trademark registrations for the graphic logo "Aviator" for gambling services including online and physical casino services and gambling. In 2021-2022, Spribe Oundefined registered its own "Aviator" trademarks for computer games and gambling services, which the claimant argued were infringing on their original trademark. The court ruled that trademarks of Spribe Oundefined were registered in bad faith, and that the trademarks of Spribe Oundefined infringed copyright on the claimant's image. As for the claim against online gambling platform www.adjarabet.com the court ruled in favor of the claimant, ordered the platform to stop the use of the name Aviator for its flagship game and online streaming of the casino games. The court has awarded Aviator LLC $330M in compensation for trademark and copyright infringement for prior illegal use.

06:12 EDT Gogoro and Nebula Energy announce commercial launch in Kathmandu for October - Nebula Energy and Gogoro announced commercial availability of Gogoro's battery swapping and Smartscooters in the Kathmandu Valley slated for October 2024. The companies introduced two new Gogoro Smartscooters to Nepal - the Pulse and JEGO - in addition to the existing CrossOver GX250 that are exclusively available through Nebula Energy. They also announced the locations for 45 battery swapping stations in Kathmandu Valley. Nebula will open the first Gogoro showroom in Kathmandu in September 2024 and customers will have the opportunity to test ride the Smartscooters and make pre-bookings at a special introductory price for delivery in October 2024. Nebula announced the locations of 45 battery swapping stations around the Kathmandu valley ensuring that there is a battery swapping station every 2-3 kilometers. Eventually, Nebula Energy plans to install more battery swapping stations than the number of petrol stations in Nepal.

06:10 EDT ACI Worldwide's Digital Central Infrastructure solution adopted by Mexipay - ACI Worldwide and Mexipay, a Mexican financial technology company, are extending of their partnership to enhance Mexico's real-time payments ecosystem, with the aim of driving instant payments adoption. Mexipay will utilize ACI's Digital Central Infrastructure solution, part of the ACI Enterprise Payments Platform, to address the need for enhanced real-time payment services.

06:05 EDT Accenture to acquire consus.health in Germany - Accenture has agreed to acquire consus.health, a German healthcare management consultancy. consus.health offers services ranging from medical strategy and patient management to procurement and logistics, infrastructure management and construction planning services. Founded in 2012, consus.health has a presence in the German market serving more than 600 healthcare providers and hospitals aiming to improve the financial and operational performance of its clients. Headquartered in Freiburg im Breisgau, consus.health's team of 140 experts will join Accenture's Health Strategy & Consulting practice in Germany. Terms of the transaction were not disclosed. Completion of the acquisition is subject to customary closing conditions.

06:00 EDT Hershey shares fall 1% to $193.80 after Citi downgrades to Sell

05:55 EDT Boeing expects China commercial fleet to more than double by 2043 - China will more than double its commercial airplane fleet by 2043 as its aviation industry expands and modernizes to meet growing demand for passenger and cargo air travel, according to Boeing's 2024 Commercial Market Outlook for China, the company's long-term forecast of demand for commercial airplanes and related services. "China's commercial aviation market for passengers and cargo continues to expand, driven by economic growth and airlines building their in-country networks," said Darren Hulst, Boeing vice president of Commercial Marketing. "As this forecast shows, China's airlines will see strong demand, requiring further growth of their modern fuel-efficient fleets." China's commercial fleet will grow 4.1% annually, from 4,345 to 9,740 airplanes by 2043, and its annual passenger traffic growth of 5.9% will exceed the global average of 4.7%, according to the CMO. Passenger volumes will receive a boost as airlines grow their networks by connecting major hubs to smaller cities.

05:49 EDT Paramount drops 4% to $10.90 after competing offer time period ends